Qin Tiejun相关文献与解析，生知库 | 链接生命科学的每一步

A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms.

无效红细胞生成与骨髓增生异常综合征/肿瘤信号通路失调的相关性

Wu Junying, Liu Jinqin, Chen Jia, Yang Lin, Li Fuhui, Qin Tiejun, Xu Zefeng, Liu Jing, Zhou Jiaxi, Shi Lihong, Li Bing, Xiao Zhijian

信号转导

Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes

TP53突变在治疗相关性骨髓增生异常综合征中的分子特征和临床意义

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-025-01276-y

Bao, Zefei; Li, Bing; Qin, Tiejun; Xu, Zefeng; Qu, Shiqiang; Jia, Yujiao; Li, Chengwen; Pan, Lijuan; Gao, Qingyan; Jiao, Meng; Wang, Huijun; Sun, Qi; Xiao, Zhijian

P53

发表日期：2025

文献求助收藏

Comprehensive genomic characterization of programmed cell death-related genes to predict drug resistance and prognosis for patients with multiple myeloma

对程序性细胞死亡相关基因进行全面的基因组表征，以预测多发性骨髓瘤患者的耐药性和预后

期刊:Aging-Us

影响因子:3.9

doi:10.18632/aging.206234

Li, Yan; Wang, Fuxu; Zhao, Hongbo; Jia, Zhenwei; Liu, Xiaoyan; Cui, Guirong; Qin, Tiejun; Kong, Xiaoyang

Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion

ASXL1基因改变对伴有孤立性20q缺失的骨髓增生异常综合征的影响

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.70747

Chang, Yanan; Liu, Linlin; Cui, Chenghua; He, Jiange; Li, Chengwen; Jia, Yujiao; Zhang, Ruixue; Wu, Wanyun; Zhou, Ji; Xiao, Jigang; Xu, Zefeng; Qin, Tiejun; Sun, Qi; Wang, Huijun; Xiao, Zhijian

ASXL1

发表日期：2025

文献求助收藏

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

预测伴有SF3B1突变和血小板增多症的骨髓增生异常/骨髓增殖性肿瘤患者的生存期

期刊:Leukemia

影响因子:13.4

doi:10.1038/s41375-024-02262-2

Li, Fuhui; Qin, Tiejun; Li, Bing; Qu, Shiqiang; Pan, Lijuan; Zhang, Peihong; Sun, Qi; Cai, Wenyu; Gao, Qingyan; Jiao, Meng; Li, Junjie; Ai, Xiaofei; Ma, Jiao; Gale, Robert Peter; Xu, Zefeng; Xiao, Zhijian

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression

原发性骨髓纤维化不同阶段的非驱动突变图谱表明，ASXL1突变在疾病进展中起着关键作用。

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-023-00829-3

Yan, Xin; Xu, Zefeng; Zhang, Peihong; Sun, Qi; Jia, Yujiao; Qin, Tiejun; Qu, Shiqiang; Pan, Lijuan; Li, Zhanqi; Liu, Jinqin; Song, Zhen; Gao, Qingyan; Jiao, Meng; Gong, Jingye; Wang, Huijun; Li, Bing; Xiao, Zhijian

ASXL1

发表日期：2023

文献求助收藏

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy

一例隐匿性TNIP1::PDGFRB重排伴骨髓增生异常综合征的病例，经低剂量伊马替尼联合地西他滨治疗后，血液学和细胞遗传学均达到缓解。

期刊:Leukemia Research Reports

影响因子:0.9

doi:10.1016/j.lrr.2023.100367

Qu, Shiqiang; Yan, Yiru; Li, Chengwen; Xu, Zefeng; Cai, Wenyu; Qin, Tiejun; Zhang, Peihong; Jia, Yujiao; Pan, Lijuan; Gao, Qingyan; Li, Bing; Liu, Jinqin; Jiao, Meng; Xiao, Zhijian

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

在真实世界环境中，对新诊断的真性红细胞增多症患者进行常规干扰素α-2b与羟基脲治疗的比较：一项基于单中心286例患者的回顾性研究

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2021.280080

Liu, Dan; Xu, Zefeng; Zhang, Peihong; Qin, Tiejun; Sun, Xiujuan; Qu, Shiqiang; Pan, Lijuan; Ma, Jiao; Cai, Wenyu; Liu, Jinqin; Wang, Huijun; Sun, Qi; Shi, Zhongxun; Huang, Huijun; Huang, Gang; Gale, Robert Peter; Li, Bing; Rampal, Raajit K; Xiao, Zhijian

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant

ASXL2 突变型骨髓增生异常综合征与一种新的种系 G6b 变异有关

期刊:Leukemia Research Reports

影响因子:0.9

doi:10.1016/j.lrr.2022.100303

Qu, Shiqiang; Zhang, Donglei; Xu, Zefeng; Jia, Yujiao; Qin, Tiejun; Pan, Lijuan; Cai, Wenyu; Zhang, Yudi; Gale, Robert Peter; Xiao, Zhijian

ASXL2

发表日期：2022

文献求助收藏

Autoimmune myelofibrosis with a TLR8 gain-of-function defect

伴有TLR8功能获得性缺陷的自身免疫性骨髓纤维化

A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms.

无效红细胞生成与骨髓增生异常综合征/肿瘤信号通路失调的相关性

Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes

TP53突变在治疗相关性骨髓增生异常综合征中的分子特征和临床意义

Comprehensive genomic characterization of programmed cell death-related genes to predict drug resistance and prognosis for patients with multiple myeloma

对程序性细胞死亡相关基因进行全面的基因组表征，以预测多发性骨髓瘤患者的耐药性和预后

Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion

ASXL1基因改变对伴有孤立性20q缺失的骨髓增生异常综合征的影响

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

预测伴有SF3B1突变和血小板增多症的骨髓增生异常/骨髓增殖性肿瘤患者的生存期

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression

原发性骨髓纤维化不同阶段的非驱动突变图谱表明，ASXL1突变在疾病进展中起着关键作用。

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy

一例隐匿性TNIP1::PDGFRB重排伴骨髓增生异常综合征的病例，经低剂量伊马替尼联合地西他滨治疗后，血液学和细胞遗传学均达到缓解。

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

在真实世界环境中，对新诊断的真性红细胞增多症患者进行常规干扰素α-2b与羟基脲治疗的比较：一项基于单中心286例患者的回顾性研究

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant

ASXL2 突变型骨髓增生异常综合征与一种新的种系 G6b 变异有关